In our pre-treatment analysis, we identified that responders showed a higher frequency of proliferating CD28-expressing CD8 T cells as well as proliferating CD4 conventional T cells, suggestive of ongoing immunity, potentially encompassing anti-tumour immune responses. The gene discussed is CD8A; the disease is neoplasm.